BioWorld

Sep. 27, 2004

View Archived Issues

Advancis' Pulsys Amoxicillin Clear To Start Phase III Trials

Read More

DOV Advances Bicifadine To First Of Pivotal Study Series

Read More

CardioVascular's $20M IPO To Push Angiogenesis Work

Read More

Other News To Note

Read More

Vion Expands Triapine Trials, Moves Cloretazine To Phase III

Vion Pharmaceuticals Inc. decided to move one lead cancer drug into pivotal trials, while expanding the Phase II trials of its other one. (BioWorld Today) Read More